Alamar Biosciences, Inc. quarterly report, Q3 FY2026

Alamar Biosciences, Inc. — Form 10-Q Summary

Reporting period: Quarter and nine months ended September 30, 2026. Unaudited results are presented against the comparable 2025 periods. Alamar is a commercial-stage proteomics company selling its NULISA platform, including ARGO HT instruments, consumables and services, primarily for research use. It completed its IPO in April 2026.

Financial performance

MetricQ3 2026Q3 2025Nine months 2026Nine months 2025
Revenue$33.5m$19.9m$89.0m$49.2m
Gross profit$20.6m$11.9m$52.8m$26.9m
Gross margin61.5%59.7%59.3%54.6%
Operating expenses$35.8m$19.8m$93.8m$51.2m
Operating loss$15.1m$7.9m$41.0m$24.4m
Net loss$13.3m$8.0m$47.9m$22.7m
Net loss per share, basic and diluted$0.19$0.69$1.02$1.99

Q3 product revenue was $26.3m, including $17.8m of consumables and $8.5m of instruments; service revenue was $7.2m. For the nine months, consumables revenue grew 122% to $47.3m, instrument revenue grew 52% to $23.6m, and services revenue grew 50% to $18.1m. Management attributed growth to a larger instrument base, higher demand for multiplex panels, higher consumable prices and increased TAP services.

At September 30, 2026, cash and cash equivalents were $121.5m and short-term investments were $105.1m, or $226.6m unrestricted liquidity; restricted cash was $4.9m. Current assets were $317.7m versus current liabilities of $33.5m. The company had no borrowings outstanding, with $54.0m available under its $60.0m SVB revolving facility after $6.0m of letters of credit. Term debt had been repaid in August. Nine-month operating cash use was $46.4m, investing cash use was $109.8m, and financing cash provided was $247.8m. The filing does not provide standalone Q3 cash-flow figures.

Changes and notable items

  • Revenue increased 68% in Q3 and 81% for the nine-month period. Gross margin improved in both comparisons, primarily from a higher consumables mix, lower instrument costs and higher consumables prices.
  • Operating expenses rose faster than revenue: Q3 R&D increased 58% and SG&A 105%. Management cited expanded product development and headcount, higher stock-based compensation, and increased legal and accounting costs.
  • Nine-month net loss included a $10.0m noncash loss from remeasurement of convertible notes before their automatic conversion into common stock at the IPO. The IPO generated $197.8m net proceeds; the notes converted into 3.9m shares.
  • Common shares outstanding were 69.5m as of October 31, 2026. The basic and diluted share counts rose substantially following the IPO and conversions, so per-share comparisons are affected by the changed share base.

Outlook, risks and contingencies

  • Management expects 2026 full-year stock-based compensation expense of $13m–$15m and expects significant operating expenses and losses to continue as it invests in R&D, manufacturing and commercialization. It believes current unrestricted cash, cash equivalents and investments will fund current plans and anticipated obligations for at least 12 months; longer-term capital needs may require additional financing.
  • Alamar intends to submit the ARGO HT/DX instrument to the FDA for marketing authorization in 2027. Current products are sold for research use only; clinical or diagnostic commercialization would require applicable regulatory authorization.
  • Key disclosed risks include ongoing losses, reliance on research and academic funding, competition, variable and lengthy sales cycles, manufacturing scale and quality, single-source suppliers, tariffs and international operations, and regulatory and intellectual-property risks.
  • Olink’s Delaware patent-infringement action concerning NULISA remains pending. Alamar’s motion to dismiss the amended complaint is pending; its appeal of the PTAB decision was dismissed on October 13, 2026. The company said a loss was not probable as of September 30 and that it could not reasonably estimate a possible loss.
  • Operating lease liabilities totaled $42.4m; undiscounted future lease payments were $79.8m. The company also disclosed an ADDF research funding agreement of up to $10.0m, with a low-single-digit royalty on ARGO DX sales and potential sales milestone payments capped at $4.75m.
  • Management reported disclosure controls and procedures were effective at the reasonable-assurance level and no material change in internal control over financial reporting occurred during the quarter.

Important facts for investors to verify

  • Whether revenue and consumables demand continue to grow, and whether instrument placements translate into recurring consumables sales.
  • Whether margin improvement persists as manufacturing capacity expands and inventory reserves, product mix, pricing and tariffs change.
  • Cash-burn trends, the assumptions behind management’s at-least-12-month liquidity assessment, and any need for additional capital or dilution.
  • Progress, timing and regulatory pathway for ARGO HT/DX, including the planned 2027 FDA submission.
  • Developments in the Olink litigation and any resulting financial, operational or product implications.
  • Customer exposure to research-funding reductions, supply constraints, manufacturing quality issues and single-source suppliers.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.